Payment overview · 2025
General Payments
$821.65
12 reported records · 7 companies
Healthcare provider profile · identity verified
Moshir Jacob, MD
Allopathic & Osteopathic Physicians|Internal Medicine · TOLEDO, OH · NPI 1245237007
Verified facts
What the public records show
CMS Open Payments records show Moshir Jacob, MD received $821.65 in general payments during 2025 across 12 reported records.
Boston Scientific Corporation accounted for 34.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 398 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $283.33 | 34.5% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $165.50 | 20.1% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $136.06 | 16.6% | 2 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $108.27 | 13.2% | 1 | 2025 |
| LifeNet Health | Unresolved — no canonical attribution shown | $55.55 | 6.8% | 1 | 2025 |
| DePuy Synthes Sales Inc. | Unresolved — no canonical attribution shown | $54.03 | 6.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.91 | 2.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $821.65 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $283.33 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $124.56 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $115.31 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $108.27 | 1 | 2025 |
Source payment records
|
|||||
| Allograft VMIS Delivery System Normalized: allograft vmis delivery system |
Device | LifeNet Health | $55.55 | 1 | 2025 |
Source payment records
|
|||||
| PliaFX Flo Normalized: pliafx flo |
Device | LifeNet Health | $55.55 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $33.89 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $33.89 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $18.91 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $18.91 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $11.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 86 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
87 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
86 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
398 | 71 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 981 | 270 |
| Amlodipine Besylate | Amlodipine Besylate | 499 | 138 |
| Levothyroxine Sodium | Levothyroxine Sodium | 455 | 124 |
| Lisinopril | Lisinopril | 453 | 123 |
| Metformin Hcl | Metformin Hcl | 408 | 110 |
| Eliquis | Apixaban | 398 | 71 |
| Omeprazole | Omeprazole | 366 | 99 |
| Metoprolol Tartrate | Metoprolol Tartrate | 360 | 109 |
| Gabapentin | Gabapentin | 343 | 83 |
| Escitalopram Oxalate | Escitalopram Oxalate | 283 | 70 |
| Losartan Potassium | Losartan Potassium | 255 | 65 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 254 | 75 |
| Simvastatin | Simvastatin | 246 | 57 |
| Allopurinol | Allopurinol | 220 | 60 |
| Tamsulosin Hcl | Tamsulosin Hcl | 214 | 46 |
| Trazodone Hcl | Trazodone Hcl | 206 | 51 |
| Pantoprazole Sodium | Pantoprazole Sodium | 200 | 56 |
| Donepezil Hcl | Donepezil Hcl | 199 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 198 | 58 |
| Furosemide | Furosemide | 194 | 63 |
| Carvedilol | Carvedilol | 192 | 53 |
| Irbesartan | Irbesartan | 183 | 51 |
| Potassium Chloride | Potassium Chloride | 181 | 40 |
| Clopidogrel | Clopidogrel Bisulfate | 171 | 44 |
| Pravastatin Sodium | Pravastatin Sodium | 153 | 46 |
| Hydrochlorothiazide | Hydrochlorothiazide | 134 | 34 |
| Januvia | Sitagliptin Phosphate | 128 | 25 |
| Atenolol | Atenolol | 124 | 33 |
| Jardiance | Empagliflozin | 124 | 33 |
| Alendronate Sodium | Alendronate Sodium | 112 | 24 |
| Famotidine | Famotidine | 112 | 26 |
| Bumetanide | Bumetanide | 111 | 23 |
| Xarelto | Rivaroxaban | 109 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 108 | 29 |
| Sertraline Hcl | Sertraline Hcl | 103 | 26 |
| Montelukast Sodium | Montelukast Sodium | 98 | 30 |
| Spironolactone | Spironolactone | 96 | 25 |
| Memantine Hcl | Memantine Hcl | 95 | 22 |
| Buspirone Hcl | Buspirone Hcl | 92 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 92 | 22 |
| Alprazolam | Alprazolam | 90 | 28 |
| Farxiga | Dapagliflozin Propanediol | 87 | 20 |
| Metformin Hcl Er | Metformin Hcl | 87 | 21 |
| Ozempic | Semaglutide | 86 | 17 |
| Celecoxib | Celecoxib | 85 | 29 |
| Tizanidine Hcl | Tizanidine Hcl | 82 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 81 | 31 |
| Citalopram Hbr | Citalopram Hydrobromide | 78 | 23 |
| Prednisone | Prednisone | 77 | 48 |
| Meloxicam | Meloxicam | 72 | 20 |
| Finasteride | Finasteride | 70 | 21 |
| Glimepiride | Glimepiride | 68 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 66 | 20 |
| Levetiracetam | Levetiracetam | 66 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 61 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 60 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 58 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 56 | 21 |
| Midodrine Hcl | Midodrine Hcl | 56 | 15 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 54 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 53 | 14 |
| Baclofen | Baclofen | 51 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 51 | 14 |
| Tramadol Hcl | Tramadol Hcl | 51 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 50 | 19 |
| Mounjaro | Tirzepatide | 49 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 48 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 48 | 15 |
| Topiramate | Topiramate | 48 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 46 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 45 | 25 |
| Glipizide | Glipizide | 45 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 45 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 44 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 43 | 21 |
| Azithromycin | Azithromycin | 42 | 37 |
| Mirtazapine | Mirtazapine | 42 | 12 |
| Telmisartan | Telmisartan | 42 | 11 |
| Divalproex Sodium | Divalproex Sodium | 41 | suppressed |
| Lorazepam | Lorazepam | 40 | 11 |
| Nifedipine Er | Nifedipine | 40 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 38 | 13 |
| Lansoprazole | Lansoprazole | 37 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 37 | suppressed |
| Cilostazol | Cilostazol | 36 | suppressed |
| Entresto | Sacubitril/Valsartan | 36 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 35 | suppressed |
| Ezetimibe | Ezetimibe | 34 | suppressed |
| Ibuprofen | Ibuprofen | 34 | 18 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 33 | 13 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 33 | suppressed |
| Bupropion Xl | Bupropion Hcl | 32 | suppressed |
| Olanzapine | Olanzapine | 32 | suppressed |
| Synthroid | Levothyroxine Sodium | 32 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 31 | suppressed |
| Nystatin | Nystatin | 31 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Chlorthalidone | Chlorthalidone | 30 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 30 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 29 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | suppressed |
| Myrbetriq | Mirabegron | 29 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 29 | suppressed |
| Clonazepam | Clonazepam | 28 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 28 | suppressed |
| Fenofibrate | Fenofibrate | 28 | suppressed |
| Digoxin | Digoxin | 27 | suppressed |
| Hydrocortisone | Hydrocortisone | 26 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 26 | suppressed |
| Vascepa | Icosapent Ethyl | 26 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 25 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 25 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 25 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 25 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 24 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 24 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 24 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 16 |
| Acyclovir | Acyclovir | 23 | suppressed |
| Valsartan | Valsartan | 23 | suppressed |
| Linzess | Linaclotide | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 22 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 21 | suppressed |
| Rivastigmine | Rivastigmine | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Lidocaine | Lidocaine | 20 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 11 |
| Lactulose | Lactulose | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Clozapine | Clozapine | 16 | suppressed |
| Dantrolene Sodium | Dantrolene Sodium | 16 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 16 | suppressed |
| Pregabalin | Pregabalin | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Latanoprost | Latanoprost | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | 13 |
| Lovastatin | Lovastatin | 15 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 15 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 14 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 14 | suppressed |
| Cephalexin | Cephalexin | 14 | suppressed |
| Invokana | Canagliflozin | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 12 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 11 | suppressed |
| Lacosamide | Lacosamide | 11 | suppressed |
| Livalo | Pitavastatin Calcium | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Verapamil Sr | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $821.65 · 12 records | Boston Scientific Corporation | AIRSUPRA, Allograft VMIS Delivery System, BREZTRI, General - Pain Management, JOURNAVX, NURTEC ODT, Ozempic, PliaFX Flo, Rybelsus, Wegovy, ZAVZPRET | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error